Sales & Marketing

Aug 01, 2005
Pharmaceutical Executive
As a result of the rapid innovations in drug technology, and the increasing complexities surrounding drugs' safety, cost, and efficacy, the demand for extensive formulary reviews is growing. To keep pace, Pharmacy & Therapeutics (P&T) committees have been ardently reviewing medications to determine which ones deserve inclusion and preferred placements in health plans and formularies. While there are many factors that influence the committees' decisions, with some carrying more weight than others, pharmaceutical execs complain that there is no accurate way to predict which drugs will make the cut.
Aug 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
The world might seem large but it's actually smaller than ever. The best way to exercise a high level of quality control is to make sure that the campaigns are globalized.
Aug 01, 2005
Pharmaceutical Executive
Manufacturers will have to incorporate Part D–specific messaging into all of their current marketing materials. In addition, they should consider publication plans and CME that specifically address the needs of seniors.
Aug 01, 2005
Pharmaceutical Executive
SPCs extend a drug's basic patent protection for up to five years, to take into account the time that may have lapsed between the filing of a patent application and the granting of market authorization.
Aug 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
RSS has the power to change how users consume Web-based content, giving them control of their information and increased privacy.
Aug 01, 2005
Pharmaceutical Executive
Western pharma companies call on only China's largest hospitals in the biggest cities. By some estimates, this amounts to only 20,000 doctors.
Aug 01, 2005
Pharmaceutical Executive
With patients who suffer from poverty, lack of education, and disease, it is incredibly easy to do damage through a marketing tactic that might be acceptable for another group.
Jul 01, 2005
Pharmaceutical Executive
Accept distortions and untruths. Don't try to undo them. The point is not to win an argument; your critics' views are legitimate, irreversible realities. It's time to give the public something new to think about.
Jul 01, 2005
Pharmaceutical Executive
The cost of healthcare has become so great that it's important to review the evidence to determine whether the drug is a good value for the money. Yet, pharmacoeconomics is rarely included in the decision process.
Jul 01, 2005
Pharmaceutical Executive
By Pharmaceutical Executive Editors
These are demanding times for pharmaceutical marketers.
native1_300x100
lorem ipsum